PI3K/mTOR inhibitor CLL442
Term · Oncology and biomedicine · MLC-T-ONC-016053
A topical inhibitor of class I phosphoinositide 3-kinase (PI3K) isoforms and mammalian target of rapamycin kinase (mTOR), with potential antineoplastic activity. Upon topical administration, PI3K/mTOR inhibitor CLL442 targets and inhibits class I PI3K isoforms and mTOR kinase. This disrupts phosphorylation of substrates downstream of PI3K and mTOR and may result in apoptosis and growth inhibition in susceptible tumor cells. The PI3K/mTOR pathway is upregulated in a variety of tumor cells and plays a key role in promoting cancer cell proliferation, survival and motility.
| Identifier | MLC-T-ONC-016053 |
|---|---|
| Field | Oncology and biomedicine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-016053",
"term": "PI3K/mTOR inhibitor CLL442",
"field": "Oncology and biomedicine",
"definition": "A topical inhibitor of class I phosphoinositide 3-kinase (PI3K) isoforms and mammalian target of rapamycin kinase (mTOR), with potential antineoplastic activity. Upon topical administration, PI3K/mTOR inhibitor CLL442 targets and inhibits class I PI3K isoforms and mTOR kinase. This disrupts phosphorylation of substrates downstream of PI3K and mTOR and may result in apoptosis and growth inhibition in susceptible tumor cells. The PI3K/mTOR pathway is upregulated in a variety of tumor cells and plays a key role in promoting cancer cell proliferation, survival and motility.",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/pi3k-mtor-inhibitor-cll442/"
}
Record 13,213 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.